Chimera Bioengineering Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 20
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $23.8M
Latest Deal Amount
  • Investors
  • 9

Chimera Bioengineering General Information

Description

Developer of gene therapeutics designed to re-program the immune system and treat cancer. The company's therapeutics are immune cells hot-wired to circumvent immune evasion and redirect them to find and kill tumor cells that are decorated with a defined target antigen, enabling unresponsive patients to recover against solid tumor cancer and life-threatening toxicities.

Contact Information

Website
www.chimera.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 329 Oyster Point Boulevard
  • 3rd Floor
  • South San Francisco, CA 94080
  • United States
+1 (310) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Chimera Bioengineering Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 09-Feb-2022 $23.8M 000.00 000.00 Completed Generating Revenue
3. Accelerator/Incubator 26-Jul-2017 00000 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator 03-Mar-2015 Completed Generating Revenue
To view Chimera Bioengineering’s complete valuation and funding history, request access »

Chimera Bioengineering Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-4 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A-3 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series A-2 7,000,000 $0.001000 $0.02 $0.27 $0.27 1x $0.27 9.38%
Series A-1 24,000,000 $0.001000 $0.02 $0.33 $0.33 1x $0.33 32.15%
To view Chimera Bioengineering’s complete cap table history, request access »

Chimera Bioengineering Executive Team (5)

Name Title Board Seat Contact Info
Michon Pinnix Chief Operating Officer
Gusti Zeiner Ph.D Co-Founder, Chief Science Officer & Board Member
Wladimir Hogenhuis Chief Executive Officer
Christina Smolke Ph.D Co-Founder & Board Member
You’re viewing 4 of 5 executive team members. Get the full list »

Chimera Bioengineering Board Members (5)

Name Representing Role Since
Catherine Thodey Chimera Bioengineering Board Member 000 0000
Gusti Zeiner Ph.D Chimera Bioengineering Co-Founder, Chief Science Officer & Board Member 000 0000
Ram Shriram Chimera Bioengineering Board Member 000 0000
Scott Dylla Ph.D Self Chairman 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Chimera Bioengineering Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chimera Bioengineering Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Band of Angels Angel Group Minority 000 0000 000000 0
Kairos Ventures Venture Capital Minority 000 0000 000000 0
Life Science Angels Angel Group Minority 000 0000 000000 0
Sand Hill Angels Angel Group Minority 000 0000 000000 0
ShangBay Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial